The overall results demonstrate that imlunestrant has an adaptable safety profile with antitumor activity in ER+/HER2− advanced breast cancer, including in patients with baseline ESR1 mutations and fulvestrant- and/or CDK4/6 inhibitor-refractory disease [114]. Here, CDK4 is linked to breast carcinoma.